PSCA-CAR-YT CELL LINE HAVING SURFACE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS AND EXHIBITING CYTOTOXIC ACTIVITY ON PSCA-POSITIVE HUMAN CANCER CELLS

FIELD: medicine.SUBSTANCE: present invention relates to immunology. Disclosed is a recombinant cell line PSCA-CAR-YT, having surface expression of chimeric antigenic receptors and exhibiting cytotoxic activity with respect to PSCA-positive human cancer cells.EFFECT: present invention can find furthe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Kuligina Elena Vladimirovna, Rikhter Vladimir Aleksandrovich, Kulemzin Sergej Viktorovich, Chikaev Anton Nikolaevich, Matvienko Darya Aleksandrovna, Gorchakov Andrej Aleksandrovich, Taranin Aleksandr Vladimirovich, Smagina Anna Sergeevna, Belovezhets Tatyana Nikolaevna, Nushtaeva Anna Andreevna, Koval Olga Aleksandrovna, Volkova Olga Yurevna, Tkachenko Anastasiya Viktorovna
Format:	Patent
Sprache:	eng ; rus
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FIELD: medicine.SUBSTANCE: present invention relates to immunology. Disclosed is a recombinant cell line PSCA-CAR-YT, having surface expression of chimeric antigenic receptors and exhibiting cytotoxic activity with respect to PSCA-positive human cancer cells.EFFECT: present invention can find further application in therapy of PSCA-associated cancer.1 cl, 5 dwg, 5 ex Настоящее изобретение относится к области иммунологии. Предложена рекомбинантная клеточная линия PSCA-CAR-YT, обладающая поверхностной экспрессией химерных антигенных рецепторов и проявляющая цитотоксическую активность по отношению к PSCA-позитивным раковым клеткам человека. Данное изобретение может найти дальнейшее применение в терапии PSCA-ассоциированного рака. 5 ил., 5 пр.